<DOC>
	<DOCNO>NCT02984683</DOCNO>
	<brief_summary>Primary Objective : To select first part SAR566658 dose base Objective Response Rate ( ORR ) safety 2 dose level demonstrate second part efficacy select dose base ORR . Secondary Objectives : - To assess : - Disease Control Rate ( DCR ) , Duration Of Response ( DOR ) , Progression-Free Survival ( PFS ) , Time To Progression ( TTP ) - The impact ocular primary prophylaxis incidence keratopathies ; - The potential immunogenicity SAR566658 - To evaluate global safety profile</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety SAR566658 Treatment Patients With CA6 Positive Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>The duration study 1 patient include screen period 21 day prior first study drug administration , 3-week treatment cycle ( ) ( 30 day last SAR566658 administration ) , follow-up period . Each patient treat radiological disease progression , unacceptable toxicity , patient 's refusal study treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Measurable Metastatic triple negative breast cancer ( TNBC ) . Patients CA6positive disease . Patients receive least 1 prior chemotherapy regimen 3 advanced/metastatic disease . Prior anticancer therapy must contain anthracycline ( eg , doxorubicin ) , contraindicate , taxane ( eg , docetaxel , paclitaxel ) adjuvant/neoadjuvant metastatic setting . Exclusion criterion : Eastern Cooperative Oncology Group ( ECOG ) performance status ≥2 . Patient le 18 year old . Pregnant breastfeed woman . Patients reproductive potential agree use accept effective method contraception study treatment period 6 month follow discontinuation study drug . Wash period le 3 week 5 halflives previous antitumor chemotherapy , immunotherapy , investigational treatment . History brain metastasis ( totally resect previously irradiate nonprogressive/relapsed ) , spinal cord compression carcinomatous meningitis , new evidence brain leptomeningeal disease . Prior treatment eribulin last prior therapy prior maytansinoid treatment ( DM1 DM4 antibodydrug conjugate [ ADCs ] ) . Known intolerance infuse protein product include monoclonal antibody ADCs . Poor bone marrow reserve and/or poor organ function . Symptomatic peripheral neuropathy Grade ≥2 . Previous history chronic corneal disease ( even asymptomatic ) unresolved acute nonrecurrent corneal condition . Patients wear contact lens willing stop wearing duration study . Medical condition require concomitant administration strong CYP3A4 inhibitor , unless discontinue least 2 week 1st administration SAR566658 . Contraindications use ophthalmic vasoconstrictor and/or corticosteroid . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>